Advances in genetics have been revolutionized in the last few years. First came CRISPR, which can edit single genes, possibly preventing diseases with a single genetic determinant – raising the possibility of gene editing of children. CRISPR is too immature to be commercialized for this purpose, and this debate is speculative for now. But genome-wide association studies (GWAS) - which assesses the entire genome and can identify multiple genetic markers predictive of disease -- have made landfall and are being commercialized for that purpose.
On the literary menu this time: The disturbing past of statistics ... the intriguing past of textiles ... the hidden cost of flour ... and how we view dining out.
The California Institute of Regenerative Medicine, a state-run agency that funds stem cell research, is considering funding research on human embryos using a gene-editing technology known as CRISPR-Cas9. This could potentially allow for cures to be discovered for devastating inherited diseases.